363 related articles for article (PubMed ID: 32305248)
1. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
Qian JD; Yao TT; Wang Y; Wang GQ
Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
[TBL] [Abstract][Full Text] [Related]
2. Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.
Fang YQ; Lv DX; Jia W; Li J; Deng YQ; Wang Y; Yu M; Wang GQ
Medicine (Baltimore); 2014 Oct; 93(20):e104. PubMed ID: 25365404
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppression induces regression of fibrosis in primary biliary cholangitis with moderate-to-severe interface hepatitis.
Wang R; Lin Q; Lu Z; Wen H; Hu F; You J; He Y; Fang Y; Bian Z; Hou Q; Ju Z; Wang Y; Lian M; Xiao X; Sheng L; Guo C; Hua J; Tang R; You Z; Chen X; Gershwin ME; Huang Z; Wang Q; Miao Q; Ma X
J Autoimmun; 2024 Feb; 143():103163. PubMed ID: 38301505
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ursodeoxycholic acid combined with prednisolone and immunosuppressant triple therapy in the treatment of refractory primary biliary cholangitis.
Yao TT; Qian JD; Wang GQ
Med Clin (Barc); 2020 Aug; 155(4):165-170. PubMed ID: 32600985
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score.
Hegade VS; Khanna A; Walker LJ; Wong LL; Dyson JK; Jones DEJ
Dig Dis Sci; 2016 Oct; 61(10):3037-3044. PubMed ID: 27435324
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score.
Carbone M; Nardi A; Flack S; Carpino G; Varvaropoulou N; Gavrila C; Spicer A; Badrock J; Bernuzzi F; Cardinale V; Ainsworth HF; Heneghan MA; Thorburn D; Bathgate A; Jones R; Neuberger JM; Battezzati PM; Zuin M; Taylor-Robinson S; Donato MF; Kirby J; Mitchell-Thain R; Floreani A; Sampaziotis F; Muratori L; Alvaro D; Marzioni M; Miele L; Marra F; Giannini E; Gaudio E; Ronca V; Bonato G; Cristoferi L; Malinverno F; Gerussi A; Stocken DD; Cordell HJ; Hirschfield GM; Alexander GJ; Sandford RN; Jones DE; Invernizzi P; Mells GF;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):626-634. PubMed ID: 30017646
[TBL] [Abstract][Full Text] [Related]
7. Treatment of ursodeoxycholic acid with glucocorticoids and immunosuppressants may improve the long-term survival rate in primary biliary cholangitis patients.
Wang ZL; Jin R; Hao M; Xie YD; Liu ZC; Wang XX; Feng B
Medicine (Baltimore); 2022 Nov; 101(46):e31395. PubMed ID: 36401422
[TBL] [Abstract][Full Text] [Related]
8. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
[TBL] [Abstract][Full Text] [Related]
9. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.
Rabahi N; Chrétien Y; Gaouar F; Wendum D; Serfaty L; Chazouillères O; Corpechot C; Poupon R
Gastroenterol Clin Biol; 2010; 34(4-5):283-7. PubMed ID: 20417047
[TBL] [Abstract][Full Text] [Related]
10. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.
Ding D; Ren P; Guo G; Liu Y; Yang C; Zheng L; Jia G; Deng J; Sun R; Wang X; Zhou X; Shang Y; Han Y
Gastroenterol Hepatol; 2023 Nov; 46(9):692-701. PubMed ID: 36632973
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.
Ding D; Guo G; Liu Y; Zheng L; Jia G; Deng J; Sun R; Wang X; Guo C; Shang Y; Han Y
Hepatol Commun; 2022 Dec; 6(12):3487-3495. PubMed ID: 36213941
[TBL] [Abstract][Full Text] [Related]
13. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.
Papastergiou V; Tsochatzis EA; Rodriguez-Peralvarez M; Thalassinos E; Pieri G; Manousou P; Germani G; Rigamonti C; Arvaniti V; Karatapanis S; Burroughs AK
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1354-64. PubMed ID: 24117847
[TBL] [Abstract][Full Text] [Related]
14. [Response to Primary Biliary Cholangitis Treatment: Influencing Factors and the Role in Prognosis Prediction].
Liu Y; Fan X; Shen Y; Men R; Guo Y; Yang L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2023 Sep; 54(5):930-936. PubMed ID: 37866948
[TBL] [Abstract][Full Text] [Related]
15. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Holtmeier J; Leuschner U
Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
[TBL] [Abstract][Full Text] [Related]
16. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.
Myers RP; Swain MG; Lee SS; Shaheen AA; Burak KW
Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186
[TBL] [Abstract][Full Text] [Related]
17. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
Hirschfield GM; Dyson JK; Alexander GJM; Chapman MH; Collier J; Hübscher S; Patanwala I; Pereira SP; Thain C; Thorburn D; Tiniakos D; Walmsley M; Webster G; Jones DEJ
Gut; 2018 Sep; 67(9):1568-1594. PubMed ID: 29593060
[TBL] [Abstract][Full Text] [Related]
18. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes.
Cheung AC; Lapointe-Shaw L; Kowgier M; Meza-Cardona J; Hirschfield GM; Janssen HL; Feld JJ
Aliment Pharmacol Ther; 2016 Jan; 43(2):283-93. PubMed ID: 26559762
[TBL] [Abstract][Full Text] [Related]
19. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
20. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.
Lindor KD; Dickson ER; Jorgensen RA; Anderson ML; Wiesner RH; Gores GJ; Lange SM; Rossi SS; Hofmann AF; Baldus WP
Hepatology; 1995 Oct; 22(4 Pt 1):1158-62. PubMed ID: 7557866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]